FDA approves ultrasound using microbubble—trials begin for men with prostate cancer at Stanford
Canary prostate cancer team—PASS wins competitive NCI award
Partnership with MD Anderson to build national lung cancer screening trial
2014Continued
Clinical trials begin in partnership with El Camino Hospital for pancreatic early cancer detection
Canary Center recruits Utkan Demirci from Harvard/MIT with expertise in biomedical microfluidic technology platforms
2014Continued
CRUK launches early cancer detection initiatives in UK
OHSU launches billion-dollar early detection initiative
2015
Tom Soh recruited from UCSB—focusing on portable, rapid, and sensitive diagnostic platforms
Canary develops Canary Quantum Cloud to give researchers access to new machine-learning platform
2016
Canary Pancreas Team discovers new biomarker candidate for cancer imaging
2017
Lung cancer biomarker discovered by Canary researchers attracts interest from multiple academic institutions and industry partners who obtain licensing to do further testing
2018
Canary forges international collaborative partnerships with the University of Calgary and University of Cambridge by funding a series of early detection projects with researchers from both institutions
Canary partners with BRCA Foundation to launch new ovarian cancer initiative that examines the link between high-risk factors and early detection
2019
Launch of multi-institutional Canary High Grade Serous Ovarian Initiative
Microbubble technology approved for breast cancer
Microbubble approved for pancreatic cancer
Completion of first Early Cancer Detection Initiative pilot awards with University of Calgary
2019 Continued
Launch of ACED Alliance – The International Alliance for Cancer Early Detection: partnership between Cancer Research UK, the Canary Center at Stanford University, the University of Cambridge, the Knight Cancer Institute at OHSU, University College London and the University of Manchester
First jointly funded Early Cancer Detection Conference hosted at Stanford through the Canary Center at Stanford-Knight Cancer Institute at OHSU-Cancer Research UK collaboration
2020
In Loving Memory Sanjiv Sam Gambhir, MD, PhD
November 23, 1962 – July 18, 2020
Photoacoustic imaging trials in prostate and ovarian cancers concluded and move to national high-risk clinics
Prostate prognostic test available commercially
International lung cancer biomarker trial ongoing
Milestone enrollment of 2000 men in the Canary Prostate Active Surveillance Study (PASS)
Future GoalsContinued
Completion of partnership with CPDR (Center for Prostate Disease Research) to merge Active Surveillance cohorts with Canary PASS, creating largest representation of African Americans on an AS study
Publication of results of high profile study on commercial test for tissue-based biomarkers in the Canary Prostate Active Surveillance Study (PASS) cohort
2000
Don Listwin’s mother, Grace Listwin, misdiagnosed with bladder infection
2001
Grace Listwin dies of late-stage ovarian cancer due to detection of her cancer at a late stage
2002
Ovarian cancer biomarker work for Dr. Nicole Urban funded by Listwin Family Foundation at the Fred Hutch Cancer Research Center (FHCRC) in Seattle
2003
Center of Excellence for early cancer detection established by Dr. Lee Hartwell at FHCRC focusing on cancer biomarkers
FDA approves ultrasound using microbubble—trials begin for men with prostate cancer at Stanford
Canary prostate cancer team—PASS wins competitive NCI award
Partnership with MD Anderson to build national lung cancer screening trial
2014 Continued
Clinical trials begin in partnership with El Camino Hospital for pancreatic early cancer detection
Canary Center recruits Utkan Demirci from Harvard/MIT with expertise in biomedical microfluidic technology platforms
2014 Continued
CRUK launches early cancer detection initiatives in UK
OHSU launches billion-dollar early detection initiative
2015
Tom Soh recruited from UCSB—focusing on portable, rapid, and sensitive diagnostic platforms
Canary develops Canary Quantum Cloud to give researchers access to new machine-learning platform
2016
Canary Pancreas Team discovers new biomarker candidate for cancer imaging
2017
Lung cancer biomarker discovered by Canary researchers attracts interest from multiple academic institutions and industry partners who obtain licensing to do further testing
2018
Canary forges international collaborative partnerships with the University of Calgary and University of Cambridge by funding a series of early detection projects with researchers from both institutions
Canary partners with BRCA Foundation to launch new ovarian cancer initiative that examines the link between high-risk factors and early detection
2019
Launch of multi-institutional Canary High Grade Serous Ovarian Initiative
Microbubble technology approved for breast cancer
Microbubble approved for pancreatic cancer
Completion of first Early Cancer Detection Initiative pilot awards with University of Calgary
2019 Continued
Launch of ACED Alliance – The International Alliance for Cancer Early Detection: partnership between Cancer Research UK, the Canary Center at Stanford University, the University of Cambridge, the Knight Cancer Institute at OHSU, University College London and the University of Manchester
First jointly funded Early Cancer Detection Conference hosted at Stanford through the Canary Center at Stanford-Knight Cancer Institute at OHSU-Cancer Research UK collaboration
2020
In Loving Memory Sanjiv Sam Gambhir, MD, PhD
November 23, 1962 – July 18, 2020
Photoacoustic imaging trials in prostate and ovarian cancers concluded and move to national high-risk clinics
Prostate prognostic test available commercially
International lung cancer biomarker trial ongoing
Milestone enrollment of 2000 men in the Canary Prostate Active Surveillance Study (PASS)
Future Goals Continued
Completion of partnership with CPDR (Center for Prostate Disease Research) to merge Active Surveillance cohorts with Canary PASS, creating largest representation of African Americans on an AS study
Publication of results of high profile study on commercial test for tissue-based biomarkers in the Canary Prostate Active Surveillance Study (PASS) cohort